Metabolic syndrome and transaminases: systematic review and meta-analysis.
Alanine transaminase
Aspartate aminotransferase
Biologic marker
Gamma-glutamyltransferase
Metabolic syndrome
Journal
Diabetology & metabolic syndrome
ISSN: 1758-5996
Titre abrégé: Diabetol Metab Syndr
Pays: England
ID NLM: 101488958
Informations de publication
Date de publication:
30 Oct 2023
30 Oct 2023
Historique:
received:
25
07
2023
accepted:
24
10
2023
medline:
30
10
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
Metabolic syndrome (MetS) is a group of metabolic abnormalities characterised by hypertension, central obesity, dyslipidaemia and dysregulation of blood glucose, associated with the risk of diabetes, cardiovascular disease and overall mortality. The presence of elevated liver enzymes may precede the development of MetS, with alterations of the liver being observed that are directly related to metabolic problems. The study aims to provide the best evidence on the association between liver enzymes (ALT, AST, GGT) and MetS by determining the effect size of these biomarkers. A systematic review and meta-analysis of studies indexed in PubMed and Scopus databases were performed. Study quality was assessed using the STROBE tool. The Grade Pro tool was used to evaluate the evidence, and the quantitative synthesis was performed using RevMan (Cochrane Collaboration). Seventeen articles comparing liver enzyme concentrations between 76,686 with MetS (MetS+) and 201,855 without MetS (MetS-) subjects were included. The concentration of ALT, AST and GGT in the MetS + subjects was significantly higher than in the control group 7.13 IU/L (CI95% 5.73-8.54; p < 0.00001; I The evaluation of the relationship of liver enzymes in the pathophysiological process of MetS could lead to new insights into early diagnosis.
Sections du résumé
BACKGROUND
BACKGROUND
Metabolic syndrome (MetS) is a group of metabolic abnormalities characterised by hypertension, central obesity, dyslipidaemia and dysregulation of blood glucose, associated with the risk of diabetes, cardiovascular disease and overall mortality. The presence of elevated liver enzymes may precede the development of MetS, with alterations of the liver being observed that are directly related to metabolic problems. The study aims to provide the best evidence on the association between liver enzymes (ALT, AST, GGT) and MetS by determining the effect size of these biomarkers.
METHODS
METHODS
A systematic review and meta-analysis of studies indexed in PubMed and Scopus databases were performed. Study quality was assessed using the STROBE tool. The Grade Pro tool was used to evaluate the evidence, and the quantitative synthesis was performed using RevMan (Cochrane Collaboration).
RESULTS
RESULTS
Seventeen articles comparing liver enzyme concentrations between 76,686 with MetS (MetS+) and 201,855 without MetS (MetS-) subjects were included. The concentration of ALT, AST and GGT in the MetS + subjects was significantly higher than in the control group 7.13 IU/L (CI95% 5.73-8.54; p < 0.00001; I
CONCLUSIONS
CONCLUSIONS
The evaluation of the relationship of liver enzymes in the pathophysiological process of MetS could lead to new insights into early diagnosis.
Identifiants
pubmed: 37899468
doi: 10.1186/s13098-023-01200-z
pii: 10.1186/s13098-023-01200-z
pmc: PMC10614379
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
220Informations de copyright
© 2023. The Author(s).
Références
Int J Environ Res Public Health. 2016 Feb 17;13(2):223
pubmed: 26901209
Sci Rep. 2015 Aug 13;5:13058
pubmed: 26269425
Atherosclerosis. 2013 Apr;227(2):398-403
pubmed: 23390894
Circulation. 2004 Jan 27;109(3):433-8
pubmed: 14744958
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Int J Environ Res Public Health. 2018 Aug 05;15(8):
pubmed: 30081587
J Clin Med. 2022 Feb 11;11(4):
pubmed: 35207209
Int J Environ Res Public Health. 2021 Sep 17;18(18):
pubmed: 34574750
Int Heart J. 2019 Jul 27;60(4):830-835
pubmed: 31257332
Curr Hypertens Rep. 2018 Feb 26;20(2):12
pubmed: 29480368
PLoS One. 2017 Sep 15;12(9):e0185040
pubmed: 28915276
Endocr J. 2017 Nov 29;64(11):1105-1114
pubmed: 28867686
Endocrinol Metab (Seoul). 2019 Dec;34(4):390-397
pubmed: 31884739
World J Diabetes. 2015 Apr 15;6(3):456-80
pubmed: 25897356
Med Sci Monit. 2020 Jan 20;26:e916459
pubmed: 31958336
Diabetes Metab Res Rev. 2021 Nov;37(8):e3452
pubmed: 33759300
J Int Med Res. 2021 Jan;49(1):300060520986311
pubmed: 33446006
Metabolism. 2014 Dec;63(12):1542-52
pubmed: 25267016
Aliment Pharmacol Ther. 2018 Nov;48(9):993-1002
pubmed: 30277595
Nihon Naika Gakkai Zasshi. 2005 Apr 10;94(4):794-809
pubmed: 15865013
Gastroenterol Res Pract. 2017;2017:9279836
pubmed: 28194177
Diabetes Care. 2018 Feb;41(2):372-382
pubmed: 29358469
Atherosclerosis. 2007 Apr;191(2):391-6
pubmed: 16682043
Nutr Clin Pract. 2011 Oct;26(5):565-76
pubmed: 21947639
Diabetes. 2004 Nov;53(11):2855-60
pubmed: 15504965
Lancet. 2005 Sep 24-30;366(9491):1059-62
pubmed: 16182882
Endocrinol Metab Clin North Am. 2008 Dec;37(4):841-56
pubmed: 19026935
Gac Sanit. 2008 Mar-Apr;22(2):144-50
pubmed: 18420014
Ann Med. 2012 Mar;44(2):187-95
pubmed: 21254896
Int J Clin Pract. 2012 Jul;66(7):692-8
pubmed: 22698421
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
PLoS One. 2017 Jul 7;12(7):e0180687
pubmed: 28686726
Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):127-33
pubmed: 17095717
Diabetes. 2011 Aug;60(8):2011-7
pubmed: 21788578
PLoS One. 2020 Aug 31;15(8):e0238388
pubmed: 32866186
Liver Int. 2016 May;36(5):713-20
pubmed: 26444696
Metab Syndr Relat Disord. 2018 Jun;16(5):232-239
pubmed: 29688806
Hypertens Res. 2010 Jun;33(6):546-7
pubmed: 20463681
J Diabetes Res. 2017;2017:9294038
pubmed: 28840131
J Clin Gastroenterol. 2014 Nov-Dec;48(10):883-8
pubmed: 24440936
Diabetes Res Clin Pract. 2017 Jul;129:136-143
pubmed: 28527304
Dig Liver Dis. 2015 Mar;47(3):181-90
pubmed: 25739820
J Occup Health. 2020 Jan;62(1):e12109
pubmed: 32515888
Int J Clin Pract. 2015 Jan;69(1):136-44
pubmed: 25363194
Diabetes Metab Syndr Obes. 2020 Apr 22;13:1281-1288
pubmed: 32368121
Metab Syndr Relat Disord. 2011 Aug;9(4):305-11
pubmed: 21495862
Int J Environ Res Public Health. 2022 Mar 19;19(6):
pubmed: 35329357
Cardiovasc Diabetol. 2018 Aug 31;17(1):122
pubmed: 30170598
Front Cardiovasc Med. 2020 Feb 25;7:22
pubmed: 32158768
Open Med (Wars). 2018 May 09;13:172-177
pubmed: 29756053
Med Clin (Barc). 2010 Oct 9;135(11):507-11
pubmed: 20206945
J Gastroenterol Hepatol. 2013 Dec;28 Suppl 4:64-70
pubmed: 24251707
Biomed Res Int. 2021 Jun 11;2021:5584452
pubmed: 34235221
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
J Gastroenterol Hepatol. 2016 May;31(5):936-44
pubmed: 26667191
Exp Gerontol. 2018 Jun;106:132-136
pubmed: 29499373
Front Public Health. 2021 Oct 12;9:743731
pubmed: 34712642
J Clin Epidemiol. 2011 Apr;64(4):383-94
pubmed: 21195583
Front Public Health. 2022 Jun 09;10:902393
pubmed: 35757633